“Exelon Patch”, developed by Novartis is the first skin patch to treat patients with mild to moderate Alzheimer disease. The new therapy that has already been approved by the FDA, is said to be more compliant for it causes less incidents of nausea and vomiting.
The FDA also approved the Exelon Patch for the treatment of patients with mild to moderate Parkinson´s disease dementia, a common disorder that affects about 20 % of Parkinson patients.
Exelon Patch is a transdermal patch which can be applied to the back, the chest or the upper arm of the patient and supplies the organism with a steady bloodstream level of the drug rivastigmine for 24 hours. This method extends the drug´s tolerability and its effectiveness over a wider range of patients, e.g. those who are not able to take the oral capsule version because of the increased prevalence of gastrointestinal side effects: Due to a study the patch version resulted in three times fewer incidents of nausea and vomiting compared to the oral capsule.
The new product should be available in US pharmacies soon. It was also submitted for approval in the European Union.
Dieser Artikel ist auch auf Deutsch vorhanden, bitte klicken Sie hier, um ihn zu lesen!
Discovering knowledge about side effects needs to be faster and better. In her oration, Prof. Dr. Agnes Kant, Professor by special appointment of Innovation of Pharmacovigilance, calls for more…
A risky carotid artery operation may no longer be necessary for patients who suffer a stroke due to carotid artery narrowing, research suggests. Instead, medication-only treatment may also be viable.
Nanoplastics are not only bad for the environment: A new study has shown that minuscule particles of plastic which enter the body also can impair the effect of antibiotic treatment.
This website uses cookies to give our readers the best website experience. Please refer to our privacy policy to find out how we use cookies and how you can edit your preferences.